Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for UroGen Pharma's Debt-to-EBITDA or its related term are showing as below:
LTS:0XOD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.48 Med: -0.95 Max: 0
Current: -2.48
LTS:0XOD's Debt-to-EBITDA is ranked worse than 100% of 306
companies
in the Biotechnology industry
Industry Median: 1.255
vs LTS:0XOD: -2.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
UroGen Pharma Debt-to-EBITDA Related Terms
UroGen Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0XOD vs PVLA, KLRA, VCEL: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, UroGen Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
UroGen Pharma (LTS:0XOD) has a Debt-to-EBITDA of -15.48 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on UroGen Pharma. According to the industry distribution chart, UroGen Pharma ranks #999999 out of 306 companies in the Biotechnology industry.
Is UroGen Pharma's Debt-to-EBITDA too high?
UroGen Pharma's current Debt-to-EBITDA is -15.48. Based on the distribution chart, UroGen Pharma ranks #999999 out of 306 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UroGen Pharma has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Debt-to-EBITDA compare to PVLA and KLRA?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #999999 out of 306 companies for Debt-to-EBITDA. This places UroGen Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 306 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on UroGen Pharma. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Debt-to-EBITDA is -15.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.96, compared to a current price of $43.86 — trading 56.9% above its estimated fair value. The current Debt-to-EBITDA is -15.48. UroGen Pharma's overall GF Score™ is 56/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Debt-to-EBITDA is -15.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $43.86 is trading 56.9% above its estimated GF Value™ of $27.96.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
Debt-to-EBITDA: -15.48
GF Value™: $27.96 vs. price of $43.86 (56.9% above fair value)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
56GF Score
Get the complete analysis for LTS:0XOD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
